Allianz Asset Management GmbH Acquires 5,138 Shares of Insmed, Inc. $INSM

Allianz Asset Management GmbH increased its holdings in Insmed, Inc. (NASDAQ:INSM) by 6.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 80,422 shares of the biopharmaceutical company’s stock after purchasing an additional 5,138 shares during the quarter. Allianz Asset Management GmbH’s holdings in Insmed were worth $8,094,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of INSM. Cullen Frost Bankers Inc. grew its stake in shares of Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 221 shares during the last quarter. ORG Partners LLC boosted its position in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 196 shares during the last quarter. Hilltop National Bank bought a new stake in Insmed during the second quarter valued at $28,000. LRI Investments LLC bought a new stake in Insmed during the second quarter valued at $59,000. Finally, Signaturefd LLC boosted its position in Insmed by 60.0% during the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 325 shares during the last quarter.

Insmed Price Performance

INSM stock opened at $165.31 on Wednesday. The stock has a market capitalization of $34.94 billion, a PE ratio of -28.95 and a beta of 1.03. The company’s 50-day moving average is $145.35 and its 200-day moving average is $106.37. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $168.21.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.40). The company had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.Insmed’s revenue for the quarter was up 18.9% compared to the same quarter last year. During the same period last year, the company earned ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. Equities research analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the company’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $145.45, for a total value of $11,129,834.00. Following the sale, the insider owned 36,461 shares in the company, valued at $5,303,252.45. This represents a 67.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Melvin Md Sharoky sold 10,000 shares of the company’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the completion of the sale, the director owned 262,675 shares in the company, valued at $38,190,318.25. This represents a 3.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 152,657 shares of company stock worth $21,442,198 over the last ninety days. Insiders own 3.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Stifel Nicolaus upped their price target on shares of Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, August 14th. Wells Fargo & Company assumed coverage on shares of Insmed in a research report on Monday. They set an “overweight” rating and a $171.00 price target on the stock. Cowen reaffirmed a “buy” rating on shares of Insmed in a research report on Thursday, October 2nd. TD Cowen upped their price target on shares of Insmed from $154.00 to $193.00 and gave the company a “buy” rating in a research report on Thursday, October 2nd. Finally, William Blair initiated coverage on shares of Insmed in a research report on Wednesday, August 20th. They set an “outperform” rating on the stock. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $152.88.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.